Compugen Ltd. is a drug discovery company. The Company is focused on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its business model includes entering into collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements. It has established the pipeline program, consisting of targets and product candidates for applications in oncology and immunology, based on immune checkpoint regulator candidates. Potential therapeutic proteins for immunology include CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031 and CGEN-15051. Its infrastructure platforms include LEADS, MED and NexGen. Its individual discovery capabilities are mAb Target Discovery, Protein Family Members Discovery Platform and Antibody-Drug Conjugate Cancer Therapy Discovery Platform, among others.